Clinical Utility of the Apolipoprotein A2 Isoform Index as a Tumor Marker for Pancreatic Cancer. | Synapse
March 4, 2026Open Access
Clinical Utility of the Apolipoprotein A2 Isoform Index as a Tumor Marker for Pancreatic Cancer.
Puntos clave
This research aims to evaluate the effectiveness of the apolipoprotein A2 isoform index (apoA2-i) as a tumor marker for pancreatic cancer.
Analyzed the ability of the apoA2-i index to detect pancreatic cancer cases that are negative for CA19-9.
Combined the apoA2-i index with CA19-9 to assess improvements in diagnostic accuracy.
The apoA2-i index successfully identified pancreatic cancer cases not detected by CA19-9.
The combination of apoA2-i index and CA19-9 demonstrated improved diagnostic performance overall.
Resumen
The apoA2-i index can detect CA19-9-negative pancreatic cancer, and the combination of the apoA2-i index with CA19-9 enhances diagnostic performance in clinical practice.